Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Inhaled immunotherapy shows promise for canine lung cancer
The study used interleukin-15 to reinvigorate the immune system.

Research could also have benefits for humans with the disease. 

US researchers have discovered that a protein naturally produced by the body could become a vital new immunotherapy drug in the fight against cancer.

Scientists at UC Davis and other institutions conducted a trial on 21 dogs with metastatic lung disease from osteosarcoma and melanoma. For 14 days, the dogs inhaled a mist containing interleukin-15 (IL-15) - a protein previously recognised for its immunotherapy properties.

The results, published in the Journal for ImmunoTherapy of Cancer, show that amplified concentrations of IL-15 can stimulate immune system defenses against some types of cancers in dogs. 

“No one previously had administered IL-15 as an inhaled treatment in dogs to deliver it directly to the site of the cancer,” explained Dr Rober Canter, a surgical oncologist at UC Davis Comprehensive Cancer Center. “We came up with that idea as a means of reducing exposure to the rest of the body, in order to improve the benefit-risk ratio, to improve the immune stimulating effects, and to reduce toxicity.”

“In this study, we used interleukin-15 to reinvigorate the immune system to make it recognize the cancer cells that had evaded the immune system and eliminate them.”

In the first-of-its-kind trial, the dogs began to show significant responses to the protein two weeks after they begain inhaling the mist. 

In two dogs, tumours shrank dramatically – including one that went into complete remission for more than a year. Furthermore, cancer that had been growing rapidly in five other dogs stabilised for several months - with the overall response rate being close to 40 per cent.

While more research is yet to be carried out, the team hopes that its findings will also benefit humans with advanced metastatic cancer.

“As part of our comparative oncology research, we are strong advocates of clinical trials in companion dogs, especially for immunotherapy, as a way to speed bench-to-bedside translation,” added Dr Canter. “The cancers that afflict dogs, including sarcomas, brain tumors, lymphoma and melanoma, are incredibly similar to cancers that humans develop.” 

Become a member or log in to add this story to your CPD history

Webinar to explore AMR in vet dentistry

News Story 1
 The WSAVA has invited veterinary professionals to a webinar on responsible antibiotic usage in dentistry.

On 19 November 2025, at 1am, Dr J Scott Weese and Dr Brooke Niemiec will share the latest advice for antimicrobial use. They will present research on oral bacterology, and explain how attendees can choose appropriate antibiotics.

The session will cover pre-, intra- and post-operative guidelines, with recommendations for various pathologies.

The webinar is designed to support veterinary professionals to make informed decisions and tackle antimicrobial resistance.

Attendees can register here

Click here for more...
News Shorts
Bluetongue reaches Wales for first time in 2025

The Animal and Plant Health Agency (APHA) has revealed that bluetongue has been confirmed in Wales for the first time in 2025.

In their latest statistics, APHA records a total of 109 cases of BTV-3 or BTV-8 in Great Britain in the 2025-2026 vector season.

The total number of BTV-3 cases in Great Britain this season is 107. This includes 103 cases within the England restricted zone and four cases in Wales.

There has also been two cases of BTV-8, which were both in Cornwall.

As a result of the cases in Wales, a Temporary Control Zone (TCZ) is enforced in Monmouthshire. Animals can move freely under general license within the England Restricted Zone, however animals with suspected bluetongue must stay on their holding.

All premises testing positive for blue tongue can be viewed on this map.